Replies to post #218830 on Kraig Biocraft Laboratories Inc (KBLB)

[WebSlinger]

<< Funding seems great, except for we don't know >>

All of the details are filed with the SEC. The source of the toxic convertible debt is YAII (once again), interest rate is 10%, the loan is due 25 Mar 2022 (in one year), the loan is secured (against the assets and IP of the company), and there will be about 200 million shares diluted to secure the debt.

https://www.sec.gov/Archives/edgar/data/1413119/000149315221006956/form8-k.htm

In addition, the due date for the previous toxic convertible debt (for $1MM) has been bumped to Jan 2022.

NOTE: If you go to the bottom of the link above, you will see links for 8 more documents.

And this is a prime example that shows that most people will look at the PRs, but they won't look at the SEC filings. This is one reason why Kim hides many of the details in the SEC filings (eg, the reverse split).

[WebSlinger]

<< The way it is worded is very unclear (again!). >>

Yes, KBLB always twists words around. They paint a pink-sky world with pretty words on worthless paper.

According to KBLB, commercial production has been happening since 2013. LOL

And production has been "doubling" and "ramping up" for about 10 years.

And toxic convertible debt is turned into "expansion capital" or a "bridge loan".

And exclusive rights are turned into "patents".